Sahu, Aditi http://orcid.org/0000-0003-0004-3839
Kose, Kivanc http://orcid.org/0000-0003-3185-2639
Kraehenbuehl, Lukas http://orcid.org/0000-0001-5411-5661
Byers, Candice http://orcid.org/0000-0003-2526-2843
Holland, Aliya
Tembo, Teguru
Santella, Anthony
Alfonso, Anabel
Li, Madison http://orcid.org/0000-0003-2866-1436
Cordova, Miguel
Gill, Melissa
Fox, Christi
Gonzalez, Salvador
Kumar, Piyush http://orcid.org/0000-0001-6396-1165
Wang, Amber Weiching
Kurtansky, Nicholas http://orcid.org/0000-0002-6745-0386
Chandrani, Pratik http://orcid.org/0000-0003-2572-0189
Yin, Shen
Mehta, Paras
Navarrete-Dechent, Cristian
Peterson, Gary
King, Kimeil
Dusza, Stephen http://orcid.org/0000-0002-0747-2479
Yang, Ning http://orcid.org/0000-0001-5121-7208
Liu, Shuaitong
Phillips, William
Guitera, Pascale
Rossi, Anthony
Halpern, Allan
Deng, Liang http://orcid.org/0000-0002-8467-9342
Pulitzer, Melissa
Marghoob, Ashfaq
Chen, Chih-Shan Jason
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Rajadhyaksha, Milind http://orcid.org/0000-0002-6323-4547
Funding for this research was provided by:
Melanoma Research Alliance
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Harold Alfond Foundation
The Chan-Zuckerberg Initiative
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB028752)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (240771)
Article History
Received: 9 July 2021
Accepted: 12 August 2022
First Online: 9 September 2022
Competing interests
: M.G. is a consulting investigator for DBV technologies; research consultant: Dermatology Service, MSKCC. Christi Alessi-Fox: employee of and owns equity in Caliber I.D., manufacturer of the VivaScope RCM. Dr. Rossi: Mavig (travel accommodation), Merz, DynaMed, Canfield Scientific, Evolus, Biofrontera, QuantiaMD, Lam Therapeutics, Cutera (consultant); Allergan (advisory board). A.H. : consultant to Canfield Scientific and an advisory board member of Scibase. L.D. : cofounder and holds equity in IMVAQ Therapeutics, patents on applications related to work on oncolytic viral therapy (US 20220056475 A1: recombinant poxviruses for cancer immunotherapy; US 20180236062 A1: use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immume checkpoint blocking agents for solid tumors). A. M.: honorarium for dermoscopy lectures (3GEN), royalties for books/book chapters, dermoscopy equipment for testing, payment for organizing and lecturing (American Dermoscopy Meeting). C-S.J.C. : research funding from Apollo Medical Optics, Inc. Milind Rajadhyaksha: was employee of and owns equity in Caliber I.D. VivaScope is the commercial version of a laboratory prototype he developed at Massachusetts General Hospital, Harvard Medical School. T.M. has acted as a consultant for Immunogenesis, Immunos Therapeutics, Daiichi Sankyo, Leap therapeutics and Pfizer, has received research support from Adaptive Biotechnologies, Aprea, Bristol Myers Squibb, Infinity Pharmaceuticals, Kyn Therapeutics, Leap Therapeutics, Peregrine Pharmaceuticals and Surface Oncology, is a cofounder of and holds an equity in IMVAQ Therapeutics and is listed as a co-inventor on patents relating to the use of oncolytic viral therapy, alphavirus-based vaccines, antibodies targeting CD40, GITR, OX40, PD-1 and CTLA-4 and neo-antigen modelling (US 20220056475 A1: recombinant poxviruses for cancer immunotherapy; US 20210179714 A1: Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells; US 20200232040 A1: neoantigens and uses thereof for treating cancer; US 20200113984 A1: Alphavirus Replicon Particles Expressing TRP2; US 20180236062 A1: use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immume checkpoint blocking agents for solid tumors). The remaining authors declare no competing interests.